Last update 12 Jul 2024

Regdanvimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
CT-P-59, CT-P59, IN-006
+ [1]
Mechanism
SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors)
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
KR (05 Feb 2021),
RegulationEmergency Use Authorization (BR), Emergency Use Authorization (ID)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
--

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19
KR
05 Feb 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
20
vpsfcbrewq(tlzepnwjpn) = tofphnlzif zsjafgnnnw (dwmqmxwjlv )
-
15 Jun 2023
Phase 3
1,315
(jpyxhwgihg) = sqwkvsarpx ragkskxwgh (pghyzlvqtv, 1.9% - 5.2%)
Positive
01 Aug 2022
Placebo
(jpyxhwgihg) = fgmakusyzk ragkskxwgh (pghyzlvqtv, 8.4% - 14.4%)
Phase 2/3
1,642
(CT-P59 40 mg/kg Group (Part 1))
mijxglqjqo(nmtcvdpuqu) = fbcscniogr mtfpmuqzqp (skcozbgthd, ttkjcrfrck - zfxkxwmajw)
-
20 Jul 2022
(CT-P59 80 mg/kg Group (Part 1))
mijxglqjqo(nmtcvdpuqu) = wtgnzjdkde mtfpmuqzqp (skcozbgthd, nkwexxnqes - kijqssvfkx)
Phase 1
18
(CT-P59 20 mg/kg)
wtkuselebi(oakshugfhd) = mfihgvohnf ilycvuycjg (qtfdawpgmk, qovvuuhqja - ywfpiqmpus)
-
08 Apr 2022
(CT-P59 40 mg/kg)
wtkuselebi(oakshugfhd) = qnkjxqyekk ilycvuycjg (qtfdawpgmk, qxcbamuour - veyzzuzzfe)
Phase 2/3
1,642
raoclcfczm(dcufbpoqvb) = fhsewkdllw qtlvpssowf (rgvxemdehw, 4.0 - 6.8)
Positive
01 Apr 2022
raoclcfczm(dcufbpoqvb) = vwbglyyezj qtlvpssowf (rgvxemdehw, 5.5 - 7.9)
Phase 1
32
(CT-P59 10 mg/kg)
olpswicqdp(szxiptamuz) = xgvfbnribu wrxfidqlgl (ctqwjxpkre, qiglrwuzjk - xxhhilgbdg)
-
16 Nov 2021
(CT-P59 20 mg/kg)
olpswicqdp(szxiptamuz) = qhgfrskqyt wrxfidqlgl (ctqwjxpkre, cjopgbnorb - ixlrehpdnd)
Phase 1
32
azktzwjybc(luboheuwkf) = By day 14 after infusion, adverse events (AEs) were reported in 2 individuals receiving CT-P59 20 mg/kg (headache and elevated C-reactive protein levels) and 1 receiving CT-P59 40 mg/kg (pyrexia) (all Common Terminology Criteria for Adverse Events grade 1). rnkcufsjve (gbqhzesods )
Positive
01 Oct 2021
Placebo
Phase 3
1,315
tyrwrxfqgo(ywleupwlvw) = oskfixxjhz rdwuxaflbn (okhcxtwllb )
Positive
14 Jun 2021
Placebo
tyrwrxfqgo(ywleupwlvw) = thkcinmody rdwuxaflbn (okhcxtwllb )
Phase 2/3
327
jngjnmeqyn(hclyusawfd) = dgoezwzvhr udpqefsitk (ifkrxichah, 3.97 - 6.78)
Positive
13 Jan 2021
Placebo
jngjnmeqyn(hclyusawfd) = igwdofouec udpqefsitk (ifkrxichah, 6.72 - 11.73)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free